» Articles » PMID: 9563784

Quantitative Analysis of Microvascular Changes in Diffuse Astrocytic Neoplasms with Increasing Grade of Malignancy

Overview
Journal Hum Pathol
Specialty Pathology
Date 1998 May 1
PMID 9563784
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Because glioblastoma multiforme (GBM) frequently shows striking, glomeruloid microvascular proliferation (MVP), this tumor has become a strong candidate for anti-angiogenic therapy. However, the efficacy of anti-angiogenic treatment may rather be determined by the extent of classic angiogenesis with the formation of delicate microvascular sprouts. Therefore, this study differentially quantifies the microvascular changes in supratentorial diffuse astrocytic neoplasms by computerized image analysis of histological sections in which the microvessels were highlighted by a combined anti-collagen IV/MIB-1 staining. Four microvascular parameters (number, area, perimeter, diameter), the cellularity of the glial tissue, and the MIB-1 labeling index were assessed in biopsies of astrocytoma (A, n = 13), anaplastic astrocytoma (AA, n = 14), and GBM (n = 20), and in normal cerebral cortex (n = 7) and white matter (n = 7). In As and AAs, the microvascular parameters were not significantly different from each other, and the microvascular changes were generally limited compared with WM and CX. In contrast, in GBMs the microvascular parameters were highly variable, and their overall mean value was significantly increased compared with As and AAs (ranging from 1.3x for vessel diameter to 3.3x for vessel area). Our study indicates that not only glomeruloid MVP, but also classic angiogenesis, occurs mainly and only locally in GBMs. Thus, this study provides evidence that As and AAs are not good candidates for anti-angiogenic therapy. The efficacy of such therapy for GBMs awaits further evaluation.

Citing Articles

Microvasculature Features Derived from Hybrid EPI MRI in Non-Enhancing Adult-Type Diffuse Glioma Subtypes.

Arzanforoosh F, Van der Voort S, Incekara F, Vincent A, van den Bent M, Kros J Cancers (Basel). 2023; 15(7).

PMID: 37046796 PMC: 10093697. DOI: 10.3390/cancers15072135.


Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.

Goldman J, Hagiwara A, Yao J, Raymond C, Ong C, Bakhti R Front Oncol. 2022; 12:849993.

PMID: 35371980 PMC: 8964348. DOI: 10.3389/fonc.2022.849993.


Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade.

Wojtukiewicz M, Mysliwiec M, Matuszewska E, Sulkowski S, Zimnoch L, Politynska B Pathol Oncol Res. 2021; 27:605017.

PMID: 34257567 PMC: 8262224. DOI: 10.3389/pore.2021.605017.


Alternative Vascularization Mechanisms in Tumor Resistance to Therapy.

Belotti D, Pinessi D, Taraboletti G Cancers (Basel). 2021; 13(8).

PMID: 33921099 PMC: 8071410. DOI: 10.3390/cancers13081912.


A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).

Cloughesy T, Brenner A, de Groot J, Butowski N, Zach L, Campian J Neuro Oncol. 2019; 22(5):705-717.

PMID: 31844890 PMC: 7229248. DOI: 10.1093/neuonc/noz232.